Pediatric Praziquantel Consortium

The Pediatric Praziquantel Consortium supports first ever World Neglected Tropical Diseases Day

28 January 2020

This Thursday, 30 January, marks the inaugural World Neglected Tropical Diseases (NTD) Day, an initiative created to...

Consortium intensifies its focus on future access

11 October 2019

In September the Levo-Praziquantel 150mg Phase 3 trial was initiated in Kenya. With the project moving towards...

A new formulation to fight Schistosomiasis


A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more